Natalizumab may control immune checkpoint inhibitor–induced limbic encephalitis
Open Access
- 1 March 2018
- journal article
- editorial
- Published by Wolters Kluwer Health in Neurology Neuroimmunology & Neuroinflammation
- Vol. 5 (2) , e439
Abstract
No abstract availableThis publication has 13 references indexed in Scilit:
- Pembrolizumab-Induced Encephalopathy: A Review of Neurological Toxicities with Immune Checkpoint InhibitorsJournal of Thoracic Oncology, 2017
- Neurological Complications Associated With Anti–Programmed Death 1 (PD-1) AntibodiesJAMA Neurology, 2017
- Rituximab for nivolumab plus ipilimumab-induced encephalitis in a small-cell lung cancer patientAnnals of Oncology, 2017
- PD-1 Checkpoint Inhibitor Associated Autoimmune EncephalitisCase Reports in Oncology, 2017
- Neurologic Serious Adverse Events Associated with Nivolumab Plus Ipilimumab or Nivolumab Alone in Advanced Melanoma, Including a Case Series of EncephalitisThe Oncologist, 2017
- Neurologic complications of immune checkpoint inhibitorsCurrent Opinion in Neurology, 2016
- Association of Autoimmune Encephalitis With Combined Immune Checkpoint Inhibitor Treatment for Metastatic CancerJAMA Neurology, 2016
- Limbic encephalitis: a clinical‐radiological comparison between herpetic and autoimmune etiologiesEuropean Journal of Neurology, 2013
- Phase 2 Trial of Single Agent Ipilimumab (Anti-CTLA-4) for Locally Advanced or Metastatic Pancreatic AdenocarcinomaJournal of Immunotherapy, 2010
- Natalizumab for the Treatment of Multiple Sclerosis and Crohn's DiseaseAnnals of Pharmacotherapy, 2005